Supplemental Tables I and II

Published: 14 August 2020| Version 2 | DOI: 10.17632/83r5x758gh.2
Octavio Servitje


These tables summarize the reported literature on the use of systemic Rituximab in patients with primary cutaneous folicular center cell lymphomas (PCFCL) and primary cutaneous marginal zone lymphomas (PCMZL). The tables include information regarding type of lymphoma, doses, response and outcome. These data are usuful to be compared with that of our present investigation